Standout Papers

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer 2010 2026 2015 2020 2.6k
  1. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (2012)
    Sunil Verma, David Miles et al. New England Journal of Medicine
  2. CDK4/6 inhibition triggers anti-tumour immunity (2017)
    Shom Goel, Molly J. DeCristo et al. Nature
  3. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens (2017)
    Romualdo Barroso‐Sousa, William T. Barry et al. JAMA Oncology
  4. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy (2010)
    Howard A. Burris, Hope S. Rugo et al. Journal of Clinical Oncology
  5. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study (2020)
    Shanu Modi, Haeseong Park et al. Journal of Clinical Oncology
  6. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial (2014)
    Ian E. Krop, Sung‐Bae Kim et al. The Lancet Oncology
  7. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (2017)
    Véronique Dièras, David Miles et al. The Lancet Oncology
  8. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer (2015)
    Sara M. Tolaney, William T. Barry et al. New England Journal of Medicine
  9. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial (2017)
    Ian E. Krop, Sung‐Bae Kim et al. The Lancet Oncology
  10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (2019)
    Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology
  11. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors (2020)
    Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery
  12. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update (2022)
    Sharon H. Giordano, Maria Alice Franzoi et al. Journal of Clinical Oncology
  13. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study (2024)
    Aditya Bardia, Ian E. Krop et al. Journal of Clinical Oncology

Immediate Impact

13 by Nobel laureates 17 from Science/Nature 104 standout
Sub-graph 1 of 20

Citing Papers

Deciphering breast cancer: from biology to the clinic
2023 Standout
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
25 intermediate papers

Works of Ian E. Krop being referenced

CDK4/6 inhibition triggers anti-tumour immunity
2017 StandoutNature
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
2012
and 25 more

Author Peers

Author Last Decade Papers Cites
Ian E. Krop 13507 5250 3879 5566 296 18.4k
Mark D. Pegram 17466 4493 4825 8288 219 23.2k
Francisco J. Esteva 11386 3109 4529 4794 277 17.6k
Véronique Dièras 17949 9207 6141 3006 351 22.5k
Nancy U. Lin 10838 7494 3908 2226 368 16.5k
Mario Campone 14956 8736 6936 3164 532 23.2k
Sara M. Tolaney 11070 5064 3587 1954 487 14.1k
William Novotny 12249 5513 3694 2594 109 22.1k
Lyndsay N. Harris 9109 2781 5405 2921 188 14.6k
Angelo Di Leo 9688 4372 5062 1659 309 14.0k
P. Fumoleau 9431 2609 4272 2214 324 14.0k

All Works

Loading papers...

Rankless by CCL
2026